Ultragreen.ai

1.1 Identity, legal anchor, and current stage

UltraGreen.ai is no longer analyzable as a stealth or lightly disclosed startup. Public materials show a Singapore-incorporated holdco, UltraGreen.ai Limited, with registration number 202437045W, a MAS-registered prospectus dated 26 November 2025, and a full SGX Mainboard listing and AGM trail by April 2026. That legal chronology matters because it reconciles the apparently young 2024 Singapore entity with a business that publicly describes deeper operating history, six million enabled procedures since 2015, and a mature global commercial footprint for indocyanine-green fluorescence products. The practical diligence conclusion is that the company should be treated as a public growth medtech platform whose predecessor operating assets existed before the listed holdco was formed. Reusable identity for later chapters should therefore anchor on the public issuer, its fluorescence-guided surgery positioning, and its product ecosystem rather than on the misleading idea that the business is merely a one-year-old pre-commercial startup.[CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Leadership, board depth, and key-person concentration

Leadership disclosure is one of the cleaner parts of the public record. Ravinder Sajwan is consistently identified as chief executive officer and executive director, while chairman Kwa Chong Seng and independent directors Hsieh Fu Hua, Sir David Lane, Nicky Tan, and Professor Toh Han Chong give the board a mix of Singapore establishment credibility, cancer-research depth, healthcare-system exposure, and capital-markets experience. The governance package also already includes investor-relations, board-committee, and whistleblowing policies. Even so, company-overview diligence should not treat governance as de-risked. The public record concentrates strategy and business relations heavily around Sajwan, while the original-founder story of the predecessor business remains underexplained relative to the very visible board roster. That makes the company look institutionally stronger than a typical freshly listed medtech issuer, but still somewhat personality-dependent at the executive layer.[CO008, CO009, CO010, CO011, CO012, CO013]

1.3 Capital history, ownership, and public-market transition

The capital story has two distinct phases that need to be separated. First, multiple September 2025 reports and a law-firm transaction note point to a roughly US$187.5-188 million pre-IPO strategic share sale or investment associated with 65 Equity Partners, Vitruvian-linked entities, and August Global at an implied valuation of about US$1.3 billion. Second, the MAS-registered November 2025 prospectus and December 2025 listing shifted the company into a public-market frame with an offer price of US$1.45 per share, reported demand of about 13.6 times the offered book, and a large post-IPO shareholder base. Public ownership disclosures then show meaningful continuing influence from 65 Equity Partners-linked and Vitruvian-linked entities. The correct reusable conclusion is not that one valuation supersedes the other, but that the pre-IPO private mark and the public listing together show a rapid re-rating path into listed-medtech territory.[CO017, CO018, CO019, CO020, CO021, CO034]

1.4 Financial scale, public milestones, and visible caution flags

Public disclosure is already rich enough to establish operating scale. UltraGreen reported FY2025 revenue of US$142.4 million, gross profit of US$121.1 million, adjusted EBITDA of US$89.4 million, and NPAT before exceptional items of US$63.8 million, while the annual report also highlighted a net cash position of about US$176.1 million. Those are unusually strong profitability markers for a recently listed growth medtech company and they explain why later chapters should treat the business as a scaled commercial platform rather than a speculative pre-revenue imaging story. The main caution flags are definitional rather than existential: marketed-country counts vary across materials, the predecessor founder and control history are not fully transparent, and customer concentration is still not explicitly disclosed. None of these gaps invalidate the public-company thesis, but they are material enough to keep on the diligence checklist. A second caution is operational rather than cosmetic: the prospectus still described WeylChem ORGANICA as the sole API supplier at the latest practicable date, even though later FY2025 and FY2026 materials highlighted second-supplier qualification and added capacity. That sequence supports a positive scaling narrative, but it also means investors should treat supply diversification as a live execution item rather than a fully closed historical risk.[CO022, CO023, CO024, CO025, CO026, CO029]

2.1 Market boundary, substitutes, and what is actually being sold

UltraGreen is not just selling a dye, but the practical market boundary still starts with indocyanine-green consumables and the procedures where clinicians already know how to use them. The retained materials support a workflow stack that extends from IC-GREEN or Verdye into compatible cameras, then into quantification and structured reporting. That broader framing matters because it avoids two common mistakes: treating the opportunity as only a reagent niche, or treating it as all surgical-imaging spend. The sources point instead to a middle ground in which dye demand is pulled by procedure-specific clinical evidence, compatible camera availability, and growing interest in quantified decision support. The main substitutes remain white-light visualization, blue-dye or radioisotope mapping, and surgeon judgment without quantified fluorescence, so adoption depends on specific clinical jobs rather than on a generic “better imaging” narrative. That keeps the market definition disciplined for underwriting. for investors. Today.[CM001, CM002, CM003, CM019, CM020, CM026]

2.2 Sizing the market with constrained lenses instead of one generic TAM

The strongest retained sizing lens comes from the prospectus and product-sheet materials that cite Frost & Sullivan. Those sources support a 2024 global ICG market of USD 173.2 million, a 2030 projection of USD 335.4 million, and a USD 925.1 million full-penetration available market. That framing is useful because it separates today’s observed market from a fuller procedural opportunity. It also shows why adoption timing matters more than simply saying the market is large. Mature U.S. procedures still appear to be below 25% penetration, while Asia-Pacific is the fastest-growing region at 16.6% CAGR. AGM materials also describe the market as only 15% to 20% penetrated. Together, those sources support a long runway thesis, but they do not by themselves prove how quickly hospitals convert evidence into standardized purchasing.[CM004, CM005, CM006, CM007, CM008, CM009]

2.3 Buyer map and the clinical proof that unlocks recurring demand

The buyer path is procedure-led. Surgeons and service-line champions generate demand, hospital capital and formulary processes determine what camera and dye can be standardized, and recurring vial demand follows only after a protocol survives real operating-room use. That path is why the retained clinical evidence matters so much. SAGES provides the strongest colorectal support in the retained set, while breast and lymphatic-mapping evidence comes from Frontiers, PubMed, and the Indian PMC cohort. ISFGS then turns that literature into dosing and timing workflows across multiple specialties. UltraGreen’s use-case pages extend the story into procedure economics, especially for cholecystectomy and colorectal surgery. The evidence base is therefore broad enough to explain why buyers engage, but it is still uneven by indication and frequently more convincing for the dye than for any one imaging hardware vendor.[CM010, CM011, CM012, CM013, CM014, CM015]

2.4 Growth drivers, constraints, and why valuation hinges on workflow conversion

The growth case is not just more surgeries. It is publication momentum, KOL education, expanding regulatory coverage, a large installed base of compatible camera systems, and the possibility that quantification upgrades the value of the workflow over time. But the constraints are equally visible. Label scope is still procedure-specific, adverse reactions remain clinically relevant, protocol standardization is incomplete, and market-footprint definitions vary across documents. Supply concentration also matters because the prospectus still names a sole API supplier at the latest practicable date. For valuation, the most important signal is that current economics look strong even before quantification becomes material: UltraGreen’s retained FY2024 metrics imply a high-margin consumables business with pricing power. The unresolved question is how much of that value ultimately accrues to the dye, to hardware partners, or to a future quantified workflow layer. Another practical constraint is that the retained corpus has much better evidence on clinical efficacy and molecule economics than on buyer-side conversion mechanics. That imbalance is important for valuation: it supports the existence of demand, but it leaves open whether hospital committees approve cameras, protocols, and recurring procurement fast enough for software-style upside to matter on an underwriting horizon.[CM015, CM020, CM021, CM028, CM029, CM030]

2.5 Exhibits

3.1 Landscape and solution classes

UltraGreen should be compared against at least four solution classes. First are the large incumbent visualization platforms: Stryker 1688 AIM with the SPY family around it, Medtronic EleVision IR, Olympus VISERA ELITE III, KARL STORZ Rubina, and Richard Wolf System green. Second are more specialized fluorescence systems such as Hamamatsu PDE-Neo II and Getinge/Fluoptics products such as Fluobeam LS and Fluobeam LX. Third is the status quo of buying indocyanine green and using an already approved compatible camera system; Diagnostic Green’s own compatibility pages make clear that many such platforms are already on the market. Fourth is UltraGreen’s self-described integrated platform, which tries to add software quantification and cloud reporting on top of dye and camera hardware. That framing matters because the buyer is not choosing only among startups; it is often choosing whether to keep an installed incumbent tower and add ICG incrementally.[CP001, CP004, CP006, CP007, CP016, CP017]

3.2 Capability and workflow comparison

Capability breadth is where UltraGreen has a plausible strategic wedge but not a clean product superiority claim. The retained UltraGreen pages describe a bundle of dye, open-procedure imaging, AI-oriented quantification, and a cloud data layer. Competitor pages, by contrast, emphasize imaging quality, workflow, and installed-base flexibility: Medtronic highlights fluorescence signal intensity measurement in open and laparoscopic procedures, Olympus emphasizes software-driven 4K multispecialty imaging, KARL STORZ highlights 4K, 3D, and overlay modes, and Richard Wolf emphasizes simultaneous fluorescence plus white-light viewing. That means UltraGreen is differentiated less by owning fluorescence itself and more by trying to move the workflow from qualitative imaging toward standardized quantification and reporting. The risk is that this edge remains partly future tense in public materials and therefore cannot yet be treated as fully proven commercial separation. A second important buyer tradeoff is deployment ambition. If an account only wants better fluorescence visualization inside an existing tower budget, incumbent options remain credible. If it wants structured perfusion reporting, surgeon-facing quantification, and a hospital-system data trail, UltraGreen at least argues for a wider operational scope than most fetched device pages describe.[CP001, CP002, CP003, CP005, CP010, CP011]

3.3 Pricing, distribution, and switching

Pricing transparency is weak across the fetched set, so the procurement question is less about sticker price and more about bundle logic, distributor reach, and existing hardware. The official pages reviewed for Stryker, Medtronic, Olympus, KARL STORZ, Richard Wolf, and UltraGreen do not post realized contract values, and UltraGreen’s own public materials instead emphasize approvals, use cases, and platform direction. At the same time, the compatible-camera pages show that hospitals can already run ICG workflows across multiple approved systems. That lowers switching costs for buyers who already trust an incumbent tower or who want to add fluorescence without replacing their broader visualization standard. UltraGreen’s answer is bundling: AGM materials explicitly tie IC-Flow plus dye to adoption in decentralized settings, and DBS reads imaging approvals as groundwork for later dye-driven monetization. The commercial debate is therefore about attach and channel leverage, not just raw technical performance.[CP009, CP013, CP021, CP023, CP024, CP025]

3.4 Moat durability and adverse signals

The adverse case should be taken seriously. ICG itself is heavily validated, society-endorsed, and already supported by multiple compatible camera vendors, so UltraGreen does not enjoy obvious exclusivity at the chemistry layer. Incumbents also come with broader installed bases and multispecialty budget relationships. UltraGreen’s moat claim is therefore conditional: it depends on whether surgeons and hospitals value a combined dye-camera-software-data workflow enough to attach beyond the already familiar status quo. Public materials suggest management understands this, because they emphasize surgeon partnerships, software quantification, connected reporting, and dye-plus-camera bundling. But exact attach rates, realized pricing, and the degree to which data products change buying behavior remain unresolved in the retained evidence. Until those proofs are public, the most durable near-term advantage looks like clinical ecosystem curation and workflow packaging rather than unassailable proprietary hardware.[CP020, CP022, CP023, CP024, CP029, CP030]

4.1 Revenue model and disclosed FY2025 performance

UltraGreen's financial profile is best understood as a consumables-led medtech platform with optionality around imaging and software, not as a pure software issuer. The financial statements define the principal activities as sales of ICG pharmaceutical products plus diagnostic imaging analytics and software solutions, while the product stack spans IC-GREEN or Verdye, IC-Flow imaging, PerfusionWorks, and UltraGreen Data Systems. That matters because the FY2025 record does not show one monolithic SaaS line; instead it shows a business where dye volumes, procedural adoption, and a smaller software layer all contribute to revenue. The headline FY2025 numbers are strong and consistently corroborated across the annual report, financial statements, press release, and results deck. Revenue reached roughly US$142.4 million, continuing-operations revenue was US$137.9 million after isolating UltraLinQ, gross profit reached US$121.1 million at an 85.0 percent gross margin, adjusted EBITDA reached US$89.4 million, and NPAT before exceptional items reached US$63.8 million. Volume and ASP data also point to genuine operating momentum rather than accounting optics: FY2025 vial volume rose to about 987.7 thousand units and management attributed part of the uplift to US pricing actions in 3Q2025. What remains missing is product-stream precision: public disclosure does not split realized revenue cleanly between dye, imaging, software, and distributor economics.[CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Margin drivers, working capital, and unit-economics proxies

The margin story is attractive but not frictionless. Public filings show real physical-product economics underneath the headline 85 percent gross margin: FY2025 cost of sales was about US$20.9 million, inventories were about US$17.2 million at year-end, and inventory expense was about US$16.7 million. Trade receivables of about US$49.6 million and total trade and other receivables of about US$55.2 million also show that cash conversion depends on channel collections and operating discipline, not just on software-like billing. The cash-flow statement is still favorable — operating cash flow was about US$53.3 million — but the working-capital footprint means the company should be analyzed as a profitable medtech distribution-and-supply platform rather than a zero-inventory software vendor. The most important underwriting tension is that the strongest profitability disclosures are aggregate, while the weakest are stream-level. Results materials give volume, ASP, revenue, gross margin, and EBITDA, yet they still do not disclose realized pricing by geography or channel, customer concentration, CAC, payback, recurring-revenue share, or gross margin by dye versus imaging versus software. Prospectus-era risk disclosure also matters here: as of the latest practicable date, WeylChem ORGANICA was still the sole commercial API supplier, while later FY2025 and FY2026 materials presented the diversification story as already improving through a second supplier and added capacity. That is a positive trajectory, but it is still an execution bridge rather than a fully closed risk item.[CI012, CI013, CI014, CI015, CI016, CI017]

4.3 Capital adequacy, IPO mechanics, and FY2026 outlook

Capital adequacy looks solid on reported numbers. Year-end cash and cash equivalents reached about US$176.1 million, borrowings had fallen to roughly US$3.1 million, and equity had reset to about US$310.6 million. Filings explain that this was not purely organic: FY2025 included US$150.0 million of gross IPO proceeds and a US$142.8 million debt-to-equity conversion of a promissory note owed to the immediate holding company. That matters positively because it means the post-listing balance sheet is clean enough to fund expansion, but it also means investors should distinguish underlying cash generation from one-off capitalization events. Dividends of US$39.75 million and an US$8.5 million tax provision on dividend income also show that shareholder returns were already present in the financial architecture during the IPO year. IPO mechanics are well evidenced across the prospectus, MAS page, and market-data sources. UltraGreen offered 112,068,200 shares at US$1.45, while separate cornerstone agreements covered 163,793,900 vendor shares at the same price. Media coverage consequently described roughly US$400 million of capital associated with the listing process once cornerstone commitments were included. Looking forward, the cleanest management guide is the US$170 million to US$190 million FY2026 revenue range repeated in both the FY2025 deck and AGM presentation. The company clearly expects continued growth, but even here precision is imperfect: one deck frames that range as about 19 to 33 percent growth while the AGM presentation frames it as about 15 to 33 percent. The number itself is therefore more reliable than the promotional percentage framing around it.[CI018, CI019, CI020, CI021, CI022, CI023]

4.4 Financial verdict and remaining diligence blockers

The evidence-led verdict is more favorable than the market shorthand of "recent IPO medtech" would suggest. UltraGreen is not merely pre-profit or concept-stage: it entered FY2026 with audited FY2025 revenue above US$140 million, strong gross margins, strong EBITDA, positive operating cash flow, low residual borrowings, and a substantial net-cash position. Independent analyst coverage from DBS reinforced that the company had genuine earnings power even while cautioning that APAC approvals were not yet likely to move 2026 group earnings materially because the region still starts from a small base. The remaining blockers are about quality of earnings and precision of presentation rather than about whether a business exists. Public sources still do not disclose customer concentration, realized pricing by stream, recurring-revenue share, CAC or payback, or segment-level margins. Secondary definitions also drift across decks: country counts span over 35 marketed countries, 40 approved countries as at January 2026, 41 after Singapore approval, and 55-plus countries sold. Those conflicts should be preserved as evidence gaps rather than forced into a falsely exact number. The resulting underwriting stance is constructive on solvency and scale, but still conditional on management providing a tighter bridge from aggregate profitability to stream-level revenue quality.[CI024, CI026, CI028, CI032, CI033, CI034]

4.5 Exhibits

5.1 Product definition and module map

UltraGreen should be read as a workflow company built on a mature fluorescence agent rather than as a single-SKU dye vendor. The retained official pages repeatedly describe a stack that begins with IC-GREEN or Verdye, moves into IC-Flow imaging, and then tries to add PerfusionWorks quantification plus UltraGreen Data Systems reporting. That distinction matters because it explains both the upside and the ambiguity in the story. The mature part is the molecule and its procedure-level clinical workflow. The newer part is the effort to turn visual interpretation into quantified, structured decision support. The cleanest current framing is that the dye and core imaging workflow are commercial, while the data and quantification layers are strategic growth modules whose exact packaging and revenue contribution remain less fully disclosed.[CE001, CE002, CE003, CE004, CE006, CE007]

5.2 How the product is used in the operating workflow

The retained use-case and clinical pages make the workflow tangible. UltraGreen positions ICG as an intraoperative visibility tool for specific jobs such as extrahepatic-biliary visualization, colorectal-anastomosis perfusion checks, and lymphatic mapping. IC-Flow or another compatible camera captures the fluorescence signal, while the future-state pitch is that PerfusionWorks and Data Systems convert that signal into more objective, reportable insight. This is the right place to preserve an important distinction: the official pages prove strong procedure logic for the dye and for image capture, but they do not yet provide the same depth of public proof for automated interpretation. The current product is therefore best described as a clinically validated fluorescence workflow with a quantification roadmap layered on top.[CE003, CE004, CE021, CE022, CE023, CE024]

5.3 Architecture, dependencies, and what actually has to work together

The product architecture is operationally multi-layered. UltraGreen needs a pharmaceutical supply chain for ICG, approved imaging hardware, procedure protocols, and then a data layer that claims to create structured reports and decision support. That creates both differentiation and dependency. A bundled dye-to-data workflow could be harder to replace than a vial alone, but any weak link—API supply, camera approvals, integration work, or proof that quantification changes decisions—can delay the full stack. The broad compatibility ecosystem around ICG is especially double-edged: it proves interoperability and category maturity, but it also means incumbent hardware vendors still control important parts of the surgeon experience and can compress the uniqueness of the imaging layer. That creates real execution risk. Still unresolved.[CE009, CE029, CE035, CE036, CE037, CE038]

5.4 Roadmap, regulatory milestones, and the quantified-workflow transition

The roadmap evidence is good enough to establish sequence, but not good enough to eliminate ambiguity. Annual-report materials place ISO27001 in 2022, PerfusionWorks development in 2023, clinical test-site introduction in 2024, and claimed FDA 510(k) plus EU MDR filing activity in 2025. By 2026, Q1 and AGM materials shift the language toward quantification, data-enabled workflows, wound-care expansion, and broader geographic approvals. That chronology supports a real transition, not vaporware, but it also shows why diligence should not overstate readiness. The sources do not clearly say whether the software modules are broadly commercial, narrowly piloted, or sold mainly as part of bundled workflow engagements. Timing is therefore directionally encouraging and definitionally incomplete at the same time.[CE010, CE011, CE012, CE013, CE014, CE015]

5.5 Trust, safety, and quality controls

Trust evidence in the retained corpus is strongest at the dye and filing level and thinner at the software-operating level. DailyMed and the FDA label clearly define approved IC-GREEN uses and safety warnings, while the annual-report timeline cites ISO27001 certification and a 2025 FDA 510(k) event for Data Systems. The challenge is that those trust signals stop short of a detailed software-control story. There is no retained public API documentation, no named EHR integration, no public data-retention policy, and no reliability benchmark for IC-Flow. The diligence implication is not that the platform is unsafe, but that investors should separate disclosed chemical and regulatory maturity from the still-sparse disclosure around software workflow governance and device-performance specifics. That disclosure gap is exactly where management diligence should concentrate.[CE010, CE013, CE014, CE027, CE028, CE037]

5.6 Exhibits

6.1 Customer segments, buyers, and jobs to be done

UltraGreen.ai’s customer evidence points to a hospital-centered go-to-market motion with several layers of users and buyers. The end user is the surgeon and operating-room team; the institutional buyer is the hospital or distribution channel deciding whether to standardize IC-Green or Verdye, adopt IC-Flow, and eventually layer in quantification software and data workflows. The public use-cases page is useful because it defines demand in workflow terms rather than abstract AI language: laparoscopic cholecystectomy, colorectal perfusion, breast sentinel mapping, and breast reconstruction are all procedure-led jobs where better visibility can change intra-operative decisions. Public materials also imply a second layer of payer logic: hospitals care about fewer leaks, shorter stays, fewer reoperations, and surgeon confidence, while distributors and hospital systems care about regulatory approvals, training support, and fit with existing OR imaging infrastructure. That segmentation is commercially attractive because the dye business can land first, imaging can expand wallet share, and data products can become a later upsell, but the company still does not disclose revenue by segment or by buyer type.[CU001, CU002, CU003, CU004, CU005, CU006]

6.2 Named customer proof, use-case evidence, and adoption quality

The strongest customer-proof artifact in the fetched cache is the May 2026 AGM presentation, which explicitly says company revenue and data are based on a cohort of five UK hospitals: Colchester, James Paget, Ipswich, Manchester University Hospitals, and Southampton & Portsmouth. That matters because most public medtech customer pages stop at logos or generalized case studies; UltraGreen at least names a hospital cohort and ties it to real-world data. The official use-cases page then layers quantified procedure benefits on top of that proof, especially in colorectal surgery and breast workflows. Still, the evidence should be scored carefully. The five-hospital statement is cohort-level rather than account-level, so investors do not get contract size, renewal timing, whether all five hospitals are still active, or how much revenue the cohort contributes. Likewise, the company points to widespread hospital adoption and a large installed clinical evidence base, but independent customer testimonials remain sparse. The result is a customer-proof stack that is better than mere marketing but weaker than a fully disclosed named-account roster.[CU003, CU004, CU005, CU007, CU008, CU009]

6.3 Training, rollout infrastructure, and expansion motion

The customer chapter is strongest when hospital proof is read together with training and rollout infrastructure. UltraGreen is not relying only on product claims; the 1Q2026 update shows webinars, distributor training, peer-to-peer surgeon programs, and fellow sponsorships, while the products page and ISFGS resources show a deliberate clinician-education layer. That matters because fluorescence-guided surgery adoption depends on workflow confidence, dosing know-how, and procedure-specific evidence rather than on a one-time hardware sale. The March 2026 APAC approvals for India, Thailand, the Philippines, and Bangladesh also matter for customers because they open additional geographies where the same dye-imaging workflow can be sold, and DBS explicitly reads them as groundwork for future ICG adoption. Integration evidence is another positive: third-party camera-system documentation suggests hospitals can often add UltraGreen’s dye and open-procedure imaging workflow without replacing their entire installed tower ecosystem. Together, these signals support a land-expand-educate model rather than a one-off device transaction.[CU008, CU010, CU014, CU015, CU016, CU017]

6.4 Durability gaps, concentration risk, and adverse adoption signals

Public durability evidence remains the biggest hole. UltraGreen discloses no NRR, GRR, churn, renewal rate, active-hospital count, satisfaction score, or top-customer concentration metric in the fetched materials. That means investors can see meaningful adoption surfaces but cannot yet verify how sticky or diversified the customer base really is. The public story is also somewhat concentrated: the five-UK-hospital cohort is the most concrete hospital proof, while the broader hospital and surgeon claims are still mostly company-controlled. Adverse evidence exists as well, though it is product- and protocol-related rather than customer-complaint-driven. DailyMed and the FDA label both warn about hypersensitivity reactions, including anaphylaxis, and the FDA label notes reported deaths due to anaphylaxis plus temporary thyroid-iodine interference. These warnings do not negate product-market fit, but they reinforce that hospital adoption requires clinical training, protocols, and safety governance. The diligence conclusion is that the company has credible adoption proof, but public retention and concentration visibility are still materially incomplete.[CU032, CU033, CU034, CU035, CU036, CU037]

7.1 Regulatory and legal risk

UltraGreen now carries listed-company obligations as well as medtech and drug-regulatory obligations. MAS OPERA shows a lodged Product Highlights Sheet and registered prospectus, while the prospectus itself preserves a standard listed-issuer liability frame and a recent legal transition from a 2024 private Singapore holdco into a 2025 public company. The Product Highlights Sheet explicitly warns investors about principal-loss risk, and the annual-report materials preserve forward-looking statement caution around regulatory, operational, and competitive uncertainty. On the product side, the retained corpus shows two separate approval tracks: IC-Flow device clearances and Verdye dye approvals. That sequencing matters because a hardware clearance does not automatically create a monetizable market if the dye is not yet approved or if local use conditions differ. Country-footprint disclosure also needs caution because 40 approved countries, 45 IC-Flow approval territories, and 55+ sold markets are not one interchangeable metric.[CR001, CR002, CR003, CR004, CR007, CR010]

7.2 Operational, commercial, and product-attach risk

Operationally, the core franchise looks stronger than many early public medtech stories: the annual report points to a second API supplier, three supplying facilities, high capacity coverage, strong margins, and meaningful net cash. But those mitigants do not eliminate commercial execution risk. Public revenue disclosure still points overwhelmingly to ICG vial economics, while disclosed software revenue remains small and partly tied to a discontinued UltraLinQ contribution. That makes product attach the key commercial question. IPO, AGM, and DBS materials all imply the investment case depends on attaching IC-Flow and later data products to dye adoption; DBS goes further by saying earnings uplift should build progressively as dye approvals come through. If the company wins dye demand but fails to attach camera or data layers, the moat narrows toward a high-quality but more commoditized pharmaceutical-plus-distribution story.[CR011, CR012, CR013, CR014, CR021, CR022]

7.3 Partner, people, and competition risk

Leadership and ecosystem dependence remain material. Public materials consistently place strategic oversight, business relations, and a large portion of the external narrative around Ravinder Sajwan. Channel News Asia also attributes software-gap identification and application expansion to surgeon relationships, reinforcing that KOL access and founder-led relationship execution sit close to the product roadmap. At the same time, Diagnostic Green’s own compatibility pages show that many approved camera systems can already support ICG. That means UltraGreen competes against the installed-base logic of Stryker, Medtronic, Olympus or Quest-related systems, KARL STORZ, Richard Wolf, and other approved camera routes, not only against direct dye substitutes. Category adoption can therefore cut both ways: society endorsements and a larger evidence base help UltraGreen, but they also enlarge the market for bigger visualization vendors that already sit inside hospital budgets. The main people-and-partner risk is not lack of interest in fluorescence; it is whether UltraGreen can convert interest into attached revenue faster than incumbents can answer.[CR008, CR009, CR027, CR028, CR029, CR030]

7.4 Mitigations, monitoring indicators, and kill criteria

The right underwriting frame is conditional rather than binary. UltraGreen has credible mitigants in the retained corpus: public governance policies, visible SGX-era disclosure activity, multiple supply-chain reinforcement claims, strong FY2025 cash generation, and a still-expanding clinical evidence base for ICG. None of those eliminate the need for monitoring. Investors should treat approval sequencing, attach rates, and country-definition discipline as live control points. A thesis break would not require a regulatory ban; it could be a softer but still serious pattern in which device approvals do not translate into dye approvals, dye approvals do not translate into bundled revenue, or public-company disclosure around those transitions becomes confusing. Similarly, if leadership concentration proves heavier than the board and governance scaffolding can absorb, or if installed incumbent camera ecosystems limit attach economics, the valuation case should compress even with healthy near-term revenue and cash. Protocol discipline matters too: indication-specific dosing, timing, and interpretation requirements in clinical guidance mean commercialization quality can still vary even when the core dye is well known.[CR005, CR006, CR014, CR017, CR020, CR033]

8.1 Reconciling the private mark with IPO pricing

UltraGreen.ai is unusual in that both the last private step-up and the IPO price are visible enough to build a clean bridge. The strongest pre-IPO source is Allen & Gledhill, which says roughly 14.42% of UltraGreen.ai Private Limited was sold in September 2025 at a US$1.3 billion equity valuation to a syndicate including 65 Equity Partners, Vitruvian, and August Global. The prospectus then provides the public reset point: 112,068,200 shares offered at US$1.45, including 103,448,300 new shares and 8,619,900 vendor shares. Using the prospectus share split history, the best public reconstruction is about 1.103 billion post-IPO shares before any over-allotment exercise, implying around US$1.60 billion of equity value at the offer price. That means the public market cleared roughly 23% above the pre-IPO mark, which is material but not absurd for a profitable issuer coming to market with fresh capital, heavy cornerstone support, and a stronger disclosure package than private investors had.[CV001, CV002, CV003, CV005, CV006, CV007]

8.2 Demand, cornerstone backing, and aftermarket support

The demand data explain why the public valuation cleared above the last private mark. Minichart’s IPO write-up says total subscriptions and indications of interest reached 13.6 times available shares and the Singapore public offer alone was 4.5 times subscribed, while cornerstone commitments totaled US$237.5 million from 16 investors. Channel News Asia and The Straits Times then show immediate aftermarket support: the stock traded above the US$1.45 offer, with reported prints around US$1.60 and an intraday high of US$1.62. DBS later marked the stock at US$1.53 and kept a US$2.00 target. Taken together, those sources say the IPO was not merely technically completed; it was actively absorbed and, at least initially, supported by both public investors and sell-side coverage. The caution is that demand-based validation is reflexive. Oversubscription and first-day trading can justify liquidity and sentiment, but they do not substitute for detailed revenue-recognition, ARR, or concentration disclosure.[CV012, CV013, CV014, CV015, CV016, CV041]

8.3 FY2025 economics and why they matter for valuation

The key reason UltraGreen.ai can be valued more like a profitable platform than a speculative medtech listing is the FY2025 financial profile. The annual report shows US$142.4 million of revenue, 85% gross margin, about US$89.4 million of adjusted EBITDA, US$63.8 million of NPAT before exceptional items, and US$176.1 million of net cash. Those are unusually strong public-market fundamentals for a company that only listed in December 2025. They also explain why a revenue-plus-cash framework is the most defensible internal reference method here: the company has enough profitability that EV/revenue, P/E sensitivity, and cash-adjusted ranges all carry more signal than venture-style TAM narratives alone. The FY2026 guidance of US$170 million to US$190 million is important because it shows management expects another step up, but the retained Q1 materials do not publish an actual quarterly revenue or ARR number, which keeps the bridge from guidance to realized results partly opaque.[CV017, CV018, CV019, CV020, CV021, CV023]

8.4 Internal reference-point valuation with bull / base / bear ranges

Because peer data in the retained cache are thin and not cleanly comparable, the best valuation discipline is to anchor on UltraGreen.ai’s own public economics, cash balance, and forward guidance, then stress the range with conservative and aggressive EV/revenue assumptions. At the IPO price, the company traded around 11.2x FY2025 revenue and about 10.0x EV/revenue after cash. At the first-day high, those metrics moved to roughly 12.5x and 11.3x, while the DBS-marked price implied about 11.9x and 10.6x. Those are not obviously absurd given 85% gross margin and strong profitability, but they do mean a lot of the easy repricing from the US$1.3 billion private mark to public trading happened immediately. The bear, base, and bull cases therefore matter more than imperfect external comps: downside is partly cushioned by profitability and cash, upside depends on actually converting FY2026 growth into repeatable revenue quality rather than just sustaining market enthusiasm.[CV028, CV029, CV030, CV034, CV035, CV036]

8.5 Anti-thesis, adverse evidence, and what still needs proving

The anti-thesis is not that UltraGreen.ai lacks a business; it is that the market may be willing to capitalize a very good business at a price that already discounts a lot of the near-term upside. Public documents still do not reveal a post-IPO preference map beyond ordinary listed shareholders, a detailed customer concentration schedule, ARR-style recurrence, or a backlog-to-revenue bridge. AGM-era materials also do not restate a clean absolute share count, so the prospectus remains the core reference point. On top of these disclosure gaps, the FDA and DailyMed labels are a genuine adverse input: hypersensitivity reactions, including reported deaths due to anaphylaxis, are manageable but real risks that can slow hospital approvals and add support burden. The right call from public evidence alone is therefore track rather than buy: investors can monitor execution and demand without assuming that early aftermarket enthusiasm guarantees durable upside from current levels.[CV031, CV032, CV038, CV039, CV040, CV042]